Our data are consistent with the results published by Sheremata et al. (34), which showed a marked reduction in plasma levels of microparticles produced by CD31+ endothelial cells in patients with MS starting from 26 weeks of IFNb treatment. This evidence concerns the gene PECAM1 and myeloid sarcoma.